Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MicroRNA 645 (miR-645)
- Target
- miR-645
- Molecular classification
- microRNA, non-coding RNA, gene regulator, Other
01
Overview
MicroRNA 645 is a non-coding microRNA located at chromosome 20q13.13 and is frequently upregulated in colon cancer due to DNA copy number gains. Its expression promotes colorectal cancer cell proliferation, cell cycle progression, and resistance to apoptosis, largely by regulating (and partially suppressing) tumor suppressor proteins such as SOX30. Inhibition of miR-645 enhances sensitivity to chemotherapeutics (e.g., 5-fluorouracil, cisplatin), and suppresses tumor growth in vivo. Beyond colon cancer, elevated miR-645 is also associated with negative prognosis in other malignancies, including gastric cancer and head and neck squamous cell carcinoma. miR-645 acts as an oncogenic regulator and could be developed as a biomarker for early diagnosis or as a therapeutic target in cancer.
- Other names
- miR-645hsa-mir-645MIR645MIRN645
02
Mechanism of action
Inhibition/antagonism of miR-645: Reduces proliferation, increases sensitivity to apoptosis induced by chemotherapeutic agents. Overexpression/mimic of miR-645: Promotes proliferation, resistance to apoptosis
03
Biological functions
Cell proliferationCell cycle progressionResistance to apoptosisRegulation of tumor suppressors (e.g., SOX30)Anchorage-independent cell growthOther
04
Disease associations
Cancer (notably colon cancer, gastric cancer, head and neck squamous cell carcinoma, ovarian cancer)MetastasisOther
05
Safety considerations
Targeting microRNAs may have off-target effects due to the broad and often multi-target nature of microRNA–mRNA interactions.Therapeutic modulation of miR-645 could influence cell cycle regulators and apoptosis in non-tumor cells, potentially leading to toxicity.
06
Interacting drugs
5-fluorouracil
1 more in the full profile.
07
Biomarkers
Differential expression of miR-645 in colon cancer tissues relative to normal mucosa may serve as a candidate diagnostic biomarker
Beyond the preview
Go deeper on MicroRNA 645 (miR-645).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MicroRNA 645 (miR-645).